NCT04451577 (UNICODE) is a clinical trial of No intervention in COVID, sponsored by Istituto Clinico Humanitas.

Who is sponsoring NCT04451577?

NCT04451577 is sponsored by Istituto Clinico Humanitas.

What drugs are being tested in NCT04451577?

Interventions in NCT04451577: No intervention.

Is NCT04451577 still recruiting?

NCT04451577 is currently status unknown. Last updated 30 June 2020.

Last reviewed 2020-06-30 · How we verify

NCT04451577: UNICODE

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Epidemiologic, Clinical, Molecular Characteristics of Hospital Employees With or Without Covid-19 Infection

Status unknown Last updated 30 June 2020

What this trial tests

trial testing No intervention in COVID in 5,000 participants. Status unknown.

Timeline

1 June 2020

Primary endpoint
1 June 2021

1 June 2023

Quick facts

Lead sponsor	Istituto Clinico Humanitas
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	5,000
Start date	1 June 2020
Primary completion	1 June 2021
Estimated completion	1 June 2023
Sites	1 location across Italy

Drugs / interventions tested

No intervention

Conditions studied

COVID — all drugs for COVID →

Sponsor

Istituto Clinico Humanitas

Who can join

18 and older, any sex, with COVID. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The study cohort will be enrolled among all Humanitas group employees (including ICH, Humanitas University and Gavazzeni), and two validation cohorts. Participants will be asked consent for the research use of blood, pharyngeal swab, and for those hospitalized for COVID-19, also for the bronchoalveolar lavage and fecal samples. Biological samples will be used to perform cellular, microbial and molecular analyses aimed at better understanding the disease pathogenesis and the individual differences in susceptibility to the disease.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

Role of Gut Microbiome in COVID-19: An Insight Into Pathogenesis and Therapeutic Potential.
Hussain I, Cher GLY, Abid MA, Abid MB. · · 2021 · cited 53× · PMID 34721437 · DOI 10.3389/fimmu.2021.765965
Gut Microbiota Dysbiosis-Immune Hyperresponse-Inflammation Triad in Coronavirus Disease 2019 (COVID-19): Impact of Pharmacological and Nutraceutical Approaches.
Ferreira C, Viana SD, Reis F. · · 2020 · cited 44× · PMID 33019592 · DOI 10.3390/microorganisms8101514
BNT162b2 vaccine induces antibody release in saliva: a possible role for mucosal viral protection?
Darwich A, Pozzi C, Fornasa G, Lizier M, et al · · 2022 · cited 32× · PMID 35393790 · DOI 10.15252/emmm.202115326
A 'Multiomic' Approach of Saliva Metabolomics, Microbiota, and Serum Biomarkers to Assess the Need of Hospitalization in Coronavirus Disease 2019.
Pozzi C, Levi R, Braga D, Carli F, et al · · 2022 · cited 18× · PMID 35174369 · DOI 10.1016/j.gastha.2021.12.006

Verify or expand the search:

Other trials of No intervention

Trials testing the same drug.

NCT06643052 — Cahnge in Management of Suspected Early Onset Neonetal Sepsis After Assimilation of Early Onset Sepsis Calculator · not yet recruiting
NCT07540611 — Gonadotropin Therapy in Idiopathic Hypogonadal Non-Obstructive · NA · not yet recruiting
NCT07291778 — Doppler Evaluation for Congestive Acute Kidney Injury in Critical Illness · NA · not yet recruiting
NCT07490431 — An Observational Study to Learn More About How Elinzanetant is Used and How Well it Works for Women With Menopause Sympt · not yet recruiting
NCT07515365 — Colitis Patterns in Patients With Lower GI Symptoms · not yet recruiting

Other recruiting trials for COVID

Currently open trials in the same condition.

NCT06744660 — Clinical Validation of the Aptitude Medical Systems Metrix COVID-19 Test · NA · recruiting
NCT04910269 — Outpatient Treatment With Anti-Coronavirus Immunoglobulin · Phase 3 · recruiting
NCT04447833 — Mesenchymal Stromal Cell Therapy For The Treatment Of Acute Respiratory Distress Syndrome · Phase 1 · active not recruiting
NCT04351347 — The Efficacy of Ivermectin in Larger Doses in COVID-19 Treatment · Phase 2, PHASE3 · recruiting
NCT04382846 — Novel Regimens in COVID-19 Treatment · Phase 3 · recruiting

Other Istituto Clinico Humanitas trials

Trials by the same sponsor.

NCT06944288 — Microbiota as Early Diagnostic and predictivE Factor for Osteoarthritic Degeneration and Microbial Contamination · NA · not yet recruiting
NCT07358247 — Postoperative Outcomes of Single-stapled Anastomosis Combined With Transanal Natural Orifice Specimen Extraction · not yet recruiting
NCT07362342 — RIght VEntricle Response to Major Lung Resection in VATS and Robotic Surgery · not yet recruiting
NCT07346274 — Intra-operative Hypotension and Post-operative Lactate Level After Pancreatic-duodenectomy. · enrolling by invitation
NCT07491419 — The Impact of Fast Antimicrobial Sensitivity Testing Tools on Stewardship Antibiotic and Clinical Outcome (ACT-FAST) · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04451577 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Istituto Clinico Humanitas
Last refreshed: 30 June 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04451577.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing